Introduction Diagnostic I-123 scans have been shown to underestimate the disease burden in differentiated thyroid cancer (DTC) when compared to I-131 post-treatment scans, especially in children and patients who have had prior radioiodine (RAI) therapy and/or distant metastasis. I-124 PET/CT has been shown to be highly effective in imaging DTC-related metastatic disease. Methods We performed a systematic review and meta-analysis of studies investigating the sensitivity and specificity of I-124 PET/CT in identifying lesions amenable to RAI therapy as confirmed by I-131 post-treatment scanning. Results There were 141 patients and 415 lesions of DTC identified altogether. There was significant heterogeneity in the individual studies. The pooled sensitivity of the I-124 PET/CT in detecting lesions of differentiated thyroid cancer amenable to I-131 therapy was 94Á2% (91Á3-96Á4% CI, P < 0Á01), and the pooled specificity was 49Á0% (34Á8-63Á4% CI, P < 0Á01). The pooled positive likelihood ratio (LR) was 1Á43 (1Á05-1Á94 CI), and the pooled negative LR was 0Á28 (0Á15-0Á53 CI). Overall, the diagnostic odds ratio was 7Á90 (3Á39-18Á48 CI). There were a small but increased number of lesions identified by I-124 PET/CT that was not detected on post-treatment scan. Conclusion I-124 PET/CT is a sensitive tool to diagnose RAI avid DTC lesions, but also detects some new lesions that are not visualized on the post-treatment I-131 scan. Further, carefully designed dosimetric studies may be required to fully establish the role of I-124 PET CT for identifying potential lesions for I-131 therapy. I-124 PET/CT in patients with DTC may have other applications in specific clinical situations.
Introduction
The application of radioiodine (RAI) therapy for differentiated thyroid cancer (DTC) has become more targeted, based on compelling evidence of the indolent behaviour exhibited by a majority of these tumours. This is consonant with the current era of precision medicine, in which clinicians are challenged to identify the appropriate candidates for therapeutic interventions like RAI to optimize each patient's therapeutic benefits while minimising their risks, including those related to radiation exposure, and restraining healthcare cost. 1 Diagnostic RAI scanning in many cases is an important contributor to decision-making about potential I-131 therapy. Diagnostic I-123 scans have been shown to underestimate the disease burden in comparison with I-131 post-treatment scans, especially in children and in other patients who have had prior RAI therapy and/or distant metastasis. 2, 3 However, higher administered I-131 treatment doses are associated with greater radiation exposure. 4 The use of I-124, a positron emitting tomography tracer, in combination with computed tomography (PET/CT) has made it possible to detect and image thyroid cancer lesions with high sensitivity and resolution, providing data for 3-D radiobiology and dosimetry. 5 Several studies have shown I-124 PET/CT to be a highly effective imaging modality compared with I-131 in diagnosing DTC-related metastatic disease. 6, 7 However, it is less clear what proportion of I-124 PET/CT-identified lesions are sufficiently RAI avid for them to prove responsive to I-131 therapy.
We performed a systematic review and meta-analysis of studies investigating the sensitivity and specificity of I-124 PET/CT in identifying lesions amenable to RAI therapy as confirmed by I-131 post-treatment scanning.
Materials and methods

Eligibility criteria
A literature search was performed on I-124 PET/CT imaging associated with thyroid cancer from 2002 until 2016. Studies describing the diagnostic accuracy of I-124 scans were included in the meta-analysis. The index test was the I-124 PET/CT performed prior to RAI therapy for DTC. The reference standard was the post-treatment I-131 scan performed with planar imaging and/or SPECT/CT.
The primary analysis was performed on a lesional basis. A patient based assessment was also qualitatively performed, but as some of the studies had small study populations, statistical analysis was not performed. For the purpose of this analysis, studies with a lesion visualized on I-124 PET CT scan, which proved to be negative on an I-131 post-treatment scan were considered as false positive. There was significant heterogeneity in the study design among the analysed studies, and a lack of studies that precisely determined the effective radiation absorbed dose with 3-D lesional dosimetry.
Study selection
A comprehensive MEDLINE/PUBMED and EMBASE search was carried out using the following term -"I-124 and differentiated thyroid cancer'. This yielded 118 published reports (See Fig. 1 ). Duplicate reports, reviews, studies on technical considerations (e.g. dosimetry), case reports, and editorials and other opinion articles were excluded. When there was no lesional data due to negative findings on both I-124 PET/CT and I-131 imaging, patient-based data results were used for the purpose of the meta-analysis, assuming that a negative study with both techniques would mean a single true negative thyroid bed study.
Data extraction
Two Authors (PS and DT) reviewed the search results and confirmed the eligibility of the chosen studies. The remaining authors (PWL, WM and LS) verified the data eligibility independently. All authors contributed to the preparation of the manuscript.
Statistical analysis
Meta-DISC software was used for estimating the pooled sensitivity, diagnostic odds ratio and likelihood ratio using the randomeffects model. 8 Heterogeneity of data was tested using the i 2 as well as H value (i.e. the square root of the chi 2 heterogeneity statistic divided by its degrees of freedom). 9 Random-effects model was used to estimate the various parameters. [10] [11] [12] Analysis for pooled specificity has to be interpreted in the light of inherent differences in study design and lack of standard 3-D dosimetry.
Results
Eight studies were initially identified in the systematic review as potentially qualified for inclusion in the meta-analysis. 6, 7, [13] [14] [15] [16] [17] [18] On further assessment, three of these studies were excluded. 6, 15, 17 In the first, Van Nostrand et al. 17 compared planar imaging with 1-2 m Ci I-131 with 1Á7 m Ci I-124 PET/CT scans in which I-124 PET was reportedly superior, detecting 50% more foci than with I-131. This study was excluded because there was no data regarding the therapeutic dose administered and corresponding imaging results. In the second, Ruhlmann et al. 6 reported a 97% agreement between I-124 PET and I-131 imaging in a lesion-based assessment and 95% in a patient-based assessment, in a large cohort of patients at a single centre; but there was inadequate information on true negative studies. In the third study by Khorjekar et al., 15 83% (10/12) of persons with negative diagnostic I-123 or I-131 scans and a negative I-124 PET/CT had positive post-treatment I-131 scans; but all these positive post-treatment scan patients had received prior RAI therapy and so they were not RAI naive. After these exclusions, five studies (comprising 141 patients and 415 lesions) from the systematic review were included in the meta-analysis (See Table 1 Dx WBS, diagnostic whole body scan; PT WBS, post-therapy whole body scan; RAI, Radioiodine Ablation r TSH (Thyrogen â ) preparation; TgAb, Thyroglobulin Antibody.
*Included in the meta-analysis.
planar/SPECT/CT are shown in Table 1 (with an asterisk). The heterogeneity and inconsistency are shown in Table 2 . I² statistic describes the percentage of variation across studies due to heterogeneity rather than chance and is independent on the number of studies. 9, 19 The pooled sensitivity of 124-I PET/CT in detecting lesions of differentiated thyroid cancer amenable to I-131 therapy was 94Á2% (91Á3-96Á4% CI, I² value 87Á4%, P < 0Á01). The pooled positive likelihood ratio (LR) was 1Á43 (1Á05-1Á94 CI), and the pooled negative LR was 0Á28 (0Á15-0Á53 CI). However, the pooled specificity of I-124 PET/CT-identified lesions proving to be positive on post-treatment I-131 scanning was only 49% (35-63 CI, I
2 value 78, P < 0Á01). Overall, the diagnostic odds ratio was 7Á90 (3Á39-18Á48 CI, I² value 0Á0%). These results of the meta-analysis are summarized in Table 2 . The pooled sensitivity, pooled likelihood ratio and the diagnostic odds ratio are shown in Fig. 2a-c . These studies' data had significant heterogeneity with respect to the mean administered dose of I-131, timing of both I-124 PET/CT and I-131 SPECT/Planar imaging and the distribution of the DTC types.
Discussion
Our meta-analysis confirms that I-124 PET/CT is a highly sensitive imaging modality for detection of RAI avid metastatic DTC lesions. However, it shows that I-124 PET/CT also detects some new lesions that are not demonstrable on post-treatment I-131 scans, indicating that their RAI avidity may not be sufficient to achieve a specific activity that would deliver effective radiotherapy to lesions identified. In particular, I-124 PET CT may not perform very well on persons with prior RAI therapy as seen in the small cohort of such patients. 15 I-124 PET/CT has advantages of having a better contrast and spatial resolution due to higher energy photons, as compared to I-123 SPECT/CT. I-124 PET/CT is superior to the latter in detecting more foci of remnant tissue and metastatic lesions in a greater number of patients with DTC. 17 This high resolution and sensitivity may support planning for surgery as with other PET/CT tracers. 20 However, as this meta-analysis confirms, I-124 PET/CT detects a small but significantly increased number of lesions that are not, in fact, detected with I-131. It is possible that these lesions are in fact treated by I-131 therapy but not visualized due to the poor spatial resolution of planar/SPECT imaging as compared to PET imaging. Due to higher energy of the coincidental photons and better instrumentation, PET-based imaging systems have better contrast resolution, attenuation correction and quantification.
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While I-124 PET/CT's revelation of these lesions' presence may have other benefits in some cases, for example, offering an explanation for the degree of a patient's serum thyroglobulin elevation or identifying metastases for which other prophylactic interventions may be valuable (e.g. surgery or external radiotherapy), it is relatively nonspecific in identifying those amenable to I-131 therapy.
Given the heterogeneity of the study populations in this metaanalysis, the clinical impact of I-124 PET/CT in more aggressive subsets of DTC, like tall cell and insular variants, needs to be further demonstrated. In addition, the imaging protocol (i.e. dose and timing of acquisition.) should be standardized for future long-term prospective studies.
I-124 PET/CT may find clinical application in the following situations: (i) cases in which the I-123 scan is likely to underestimate the disease burden (e.g. children or patients with prior history of RAI therapy); (ii) for accurate assessment of residual neck cervical disease for surgery planning; (iii) for 3-D dosimetry; and (iv) detection of nonradioiodine avid lesions for additional surgery, external beam radiation and chemotherapy.
In conclusion, I-124 PET/CT is a sensitive tool to diagnose radioiodine avid DTC lesions, but also detects many lesions that are not visualized on the post-treatment I-131 scan. Further, carefully designed dosimetric studies may be required to fully establish the role of I-124 PET CT for identifying potential lesions for I-131 therapy. I-124 PET/CT in patients with DTC may have other applications in specific clinical situations.
